PROJECT

Reconstruction of Immune homeostasis

Type I natural killer T (iNKT) cells, once activated, can specifically kill tumor and infected cells, clearing those that pose a threat to the body's health. They also secrete a variety of cytokines to modulate immune responses towards a balanced state—preventing both immune suppression, which can lead to cancer or infections, and excessive immune activation, which may result in allergies or autoimmune diseases. iNKT cells play a critical role in anti-tumor, anti-infection, and immune regulation processes, significantly surpassing NK cells in function

There is a general consensus in the field about the importance of NKT cell function. However, due to their extremely low numbers in the body—constituting less than 1% of immune cells—culturing NKT cells in vitro presents a significant challenge. Currently, few institutions possess the capability to efficiently expand high-quality NKT cells in vitro globally.
Our team, led by professors from Fudan University with extensive overseas research experience, have independently developed an innovative in vitro expansion technology for iNKT cells. In the clinical study, the effect of iNKT cell therapy on solid tumors such as lymphoma, lung cancer, and pancreatic cancer has shown remarkable efficacy and safety. These findings have been published (Clin Immunol. 2022; Immunotherapy. 2022; Cancer Res Commun. 2023).

Using this NKT cell therapy, our clinical research on solid tumors such as lymphoma, lung cancer, and pancreatic cancer has shown remarkable efficacy and safety. Studies show that combining NKT cells with dendritic cells (DC) results in even stronger anti-tumor, anti-infection, and anti-aging effects. These findings have been published in high-impact international journals related to tumor immunotherapy (Clin Immunol. 2022; Immunotherapy. 2022; Cancer Res Commun. 2023, References 1–3). To date, no similar reports have been seen internationally.Humana Press, part of the globally influential Springer Nature Group, has invited our team to author a chapter on NKT cell culture technology for its Methods in Molecular Biology series. Elsevier, the world’s largest medical publisher, has included our team's findings on NKT cell and antibody combination therapy for lymphoma in its authoritative reference book on lymphoma treatment.

Over the past five years of clinical study, our iNKT cell technology has been shown not only to modulate immunity but also to regulate metabolism and improve various sub-health conditions.
Clinical studies on sub-healthy individuals have demonstrated significant benefits in controlling inflammation, allergies, blood sugar and lipids, promoting metabolism and detoxification, preventing the malignant transformation of small nodules, and preventing infections—contributing to improved physical fitness and anti-aging effects